

CYXONE

Life Science Investor
Konference
25 Oct 2023

Carl-Magnus Högerkorp
CEO



CYXONE

Disclaimer – Forward-looking Statement

This company presentation (the "**Company Presentation**"), which is personal to the recipient, is issued by Cyxone AB (the "**Company**"). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. The Company Presentation may not be reproduced, redistributed, passed on or published, in whole or in part, to any other person for any purpose. Unless otherwise stated, the Company is the source for all data contained in the Company Presentation. Such data is provided as at the date of this Company Presentation and is subject to change without notice. The Company Presentation (together with any further information which may be provided to the addressee) is made available on the condition that it is for use only by the addressee specified above for the sole purpose of evaluating the Company and shall not be passed on to any other person or copied or reproduced, copied, distributed, disclosed or published in whole or part and shall be immediately returned along with any other copies or destroyed at any time at the request of Company.

The Company Presentation is solely for your information and should not be relied upon and shall not confer rights or remedies upon, you or any of your employees, creditors, holders of securities or other equity holders or any other person. No representation or warranty, express or implied, is made by the Company or any of its directors, officers, employees, representatives, advisers or agents or any other person or entity as to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever its source, contained in this document (including any written or oral information made available to any interested party in connection thereto), and no liability whatsoever is accepted by any such person in relation to any such information or opinion. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its credit worthiness and does not purport to be all-inclusive or to contain all information that prospective investors may desire or that may be required to properly evaluate the business, prospects or value of the Company.

The information in this Company Presentation has not been independently verified. No representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. The Company or any of their respective subsidiaries or affiliates or any of such person's directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this Company Presentation or otherwise arising in connection therewith. The Company is under no obligation to submit further information. By receiving this Company Presentation and/or attending a presentation concerning the contents hereof you acknowledge that you will be solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company.

This Company Presentation includes forward-looking statements. All statements other than statements of historical fact included in this Company Presentation, including, without limitation, those regarding the Company's financial position, business strategy, management plans and objectives for future operations are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this Company Presentation and the Company expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this Company Presentation as a result of any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.



Introduction to Cyxone



Transformative therapies for autoimmune diseases

**Rheumatoid
Arthritis**




Rabeximod

Novel Disease Modifying Therapy

Prevent destruction of joint tissue, reduce pain, stiffness and other symptoms of RA


**Multiple
Sclerosis**



T20K Novel Disease Modifying Therapy

Demyelination of nerves causes MS and is driven by IL-2 release. T20K suppresses IL-2 release and the immune cells responsible for demyelination

Portfolio of assets aligning with current unmet medical needs



Team



 **CYXONE**

Highly experienced international board and team

Board of directors




Michael Oredsson



Bert Junno



Dr. Jürgen Reess



Andrew Scorey

Medical advisor



Maarten Kraan, MD, PhD
Medical advisor
Cyxone AB SAB



Rabeximod



Anna Polak-Andersen
Head of Clinical Trials
Cyxone AB



Levente Dajka
Head of Clinical Operations
Cyxone AB



Laurens van Pinxteren
PhD, Head of CMC
Cyxone AB

T20K



Christian Gruber, PhD
Assoc. Professor
MedUni Vienna
Pharmacology
Chair Cyxone AB SAB



Sally Abdelmoaty, PhD
Director
Non-Clinical Dev
Cyxone AB



Göran Verspui, PhD
Senior Director
Drug Development
Cyxone AB



T20K Multiple Sclerosis (MS)



Multiple sclerosis is an autoimmune disease with significant unmet medical needs



MS causes myelin destruction, impairing the CNS

Many patients with unmet needs



- Age 20–40
- Women 3:1
- 2.5 million patients
- Current therapies
 - May produce safety and tolerability problems
 - Many patients respond poorly


T20K impacts on disease progression at an early stage



T20K is a stabilized plant-derived peptide which modulates release of the cytokine IL-2, which have a key role in proliferation of autoimmune T cells and loss of immune tolerance

Theil et al., 2016 [\[Link\]](#)

T20K and KOR agonist demonstrate promising synergies to halt disease progression of MS models



Rabeximod
Rheumatoid arthritis
(RA)



New Opportunities - New Value Proposition - New Direction

- DMARD market disruptions reveal opportunities with substantial unmet needs
 - JAK-inhibitors receiving regulatory restrictions (2022)
 - TNF α -inhibitors meeting strong competition from many (+9) biosimilars (2023)
 - Lack of treatment options in TNF α -inhibitor inadequate responders
- Rabeximod well positioned for the current and future unmet medical needs
 - Clinical effect demonstrated in 225 patient Phase 2a trial in severe RA disease
 - Favorable safety profile (collected in 300 patients)
 - Adding value to current standard of care
- Rabeximod aimed at TNF α -inhibitor inadequate responders
 - 30-50% of patients on TNF α -inhibitors are unable to maintain low disease activity
 - Unique treatment positioning to achieve Treat-to-Target objectives

Strong demand for new drugs in Rheumatoid Arthritis



1

CHRONIC DISEASE - CAUSING JOINT DEFORMITY AND BONE EROSION

2

LIFE-LONG MULTI-TREATMENT

3

MANY DO NOT BENEFIT (30-60%) FROM CURRENT DRUG THERAPIES


4

ORAL MEDICATIONS GIVES MORE FREEDOM

5

LACK OF RESPONSE DETERMINES LONGTERM OUTCOME

Lack of treatment response engage more and more joints – new effective treatment alternatives needed




“RA is predominantly a macrophage-mediated disorder.


A **reduction** in synovial membrane **macrophage** content should be a primary aim of successful treatment for RA patients.”

M. Kraan 2001
Rheumatology (Oxford)

Rheumatoid arthritis is influenced by multiple factors acting together




Rabeximod has unique macrophage selective properties



Adapted from Huang et al, Frontiers in Immunology 2021

Rabeximod demonstrates promising effects signals in patients with uncontrolled severe RA in Phase 2a (225pt)



Rabeximod

Business case




RA treatment landscape do not provide any novel solutions to the unmet medical need


Drug	Company	Active substance (key target)	Approved Indications	Sales 2022 WW (USA) bnUSD
Humira	AbbVie	adalimumab (TNF inhibitor)	16	21.2 (17.3)*
Enbrel	Amgen Inc	etanercept (TNF inhibitor)	6	6.7 (4.4)
MabThera/Rituxan	Hoffmann-LA Roche	rituximab (anti-CD20)	5	6.1 (2.8)
Simponi	Johnson & Johnson	golimumab (TNF inhibitor)	6	5.0 (2.8)
Remicade	Johnson & Johnson	infliximab (TNF inhibitor)	8	4.8 (3.2)
Orencia	BMS	abatacept (anti-CD80/86)	3	3.3 (2.2)
Cimzia	UCB	certolizumab pegol (TNF inhibitor)	6	2.1 (1.6)
Actemra	Hoffmann-LA Roche	tocilizumab (anti-IL6)	6	1.8 (1.2)

With the US launch of 9 Humira biosimilars in 2023, AbbVie expects Humira sales to decline by 37% in the US, 2023.


Rabeximod positioned as an adjunct intervention for TNF α inhibitor inadequate responders



Established and growing RA market




Signal seeking Phase 2 studies aimed at addressing current treatment needs



Multilayered IP strategy targeting Major Markets

- Strong and highly commercially and clinically relevant protection until at least end **2042**
- Opportunity for supplementary protection certificates and patent term extensions of up to 5 additional years



Rabeximod



Novel mode of action
targeting central
disease drivers



Documented Ph2
efficacy & safety



Convenient
Non-injectable
Oral administration



Target established
and sustainable
global market



Favorable
partnership
opportunities



Strong and
value building
patent portfolio

Macrophage targeting presents new opportunities

Autoinflammation

FMF, TRAPS, HIDS, PAPA, Blau syndrome

Monogenic autoinflammatory diseases

Gout, Pseudogout, GCA, Idiopathic uveitis, Degenerative diseases, Storage diseases, Sarcoidosis, Some PsA, Acne, Takayasu disease, IBD

Polygenic autoinflammatory diseases

Spondyloarthropathy, Behcet syndrome, Uveitis (HLA-B27)

Mixed pattern diseases

RA, Autoimmune uveitis, Coeliac disease, Pernicious anemia, PBS, Pemphigus, AAV, T1DM, SSc, SLE, Anti-GBM diseases, ATD, Addison, Myasthenia gravis, DM, PM


Polygenic autoimmune diseases

ALPS, IPEX, APECED

Monogenic autoimmune diseases



Autoimmunity



Why invest?

- **Opportunity in growing market with substantial unmet medical need**
 - Very few phase 2 assets in development
 - Project well aligned for industry needs
 - Addressing inadequate response and improve patient journeys
- **De-risked asset**
 - Already in phase 2 with relevant effect signals
 - Favorable safety profile and advantageous pharmacology
 - Advanced Regulatory status
 - Opportunity to broaden into the autoimmune/autoinflammatory space
 - Good IP position and sharp patent strategy
- **Continuous value inflection points from Phase 2 PoC studies**
- **Low valuation; > 350MSEK invested**



www.cyxone.com

